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Abstract
Prediction of drug action in human cells is a major challenge in biomedical research. Additionally, there is strong interest in
finding new applications for approved drugs and identifying potential side effects. We present a computational strategy to
predict mechanisms, risks and potential new domains of drug treatment on the basis of target profiles acquired through
chemical proteomics. Functional protein-protein interaction networks that share one biological function are constructed
and their crosstalk with the drug is scored regarding function disruption. We apply this procedure to the target profile of the
second-generation BCR-ABL inhibitor bafetinib which is in development for the treatment of imatinib-resistant chronic
myeloid leukemia. Beside the well known effect on apoptosis, we propose potential treatment of lung cancer and IGF1R
expressing blast crisis.
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Introduction
Biomedical research is changing towards a systems pharmacol-
ogy view of drug action [1]. In parallel, chemical proteomics
(Figure 1), a postgenomic version of classical drug affinity
purifications which use is growing rapidly, has been developed
to measure drug target profiles in an unbiased manner [2–5]. It
usually reveals larger than expected spectra of targets which are
causing both therapeutic and adverse effects. Such unbiased target
profiles are very valuable entry points to understand which regions
of the cell machinery are perturbed by a drug. It is hence desirable
to develop new specific algorithms exploiting chemical proteomics
profiles. Generally, it is natural that protein interaction networks
are involved to characterize drug targets, action on diseases, and
potential side effects [6–11]. Existing methods are mainly based on
the network topology and on an integration of gene expression
data and phenotype similarities [12–14].
Alternatively, precise modeling of perturbations which change
the protein interaction network has the potential to predict new
drug targets and to provide a detailed mechanism of action
simultaneously [15–17]. Beside network approaches, classical gene
ontology (GO) enrichment analyses of drug targets are commonly
used which result in no detailed mechanism but identify different
processes and functions of direct involvement [11,18]. However,
one pivotal aspect is that drug targets can perturb protein
interaction networks and biological processes without being
directly part of the latter. Therefore, we present a new algorithm
which combines direct and peripheral perturbations of functional
sub-networks and exploits chemical proteomics drug target
profiles. The idea of functional sub-networks is based on the
finding that genes associated with the same disease often share
protein-protein interactions and gene ontology terms [19]. Our
algorithm estimates the drug impact on biological processes and
the detailed perturbation effects can be visualized as a network,
which facilitates interpretation. Furthermore, we introduce an
affinity score to weigh the drug target profile on the basis of
interaction strengths.
We applied our algorithm to the bafetinib (NS-187, INNO-406)
target profile. Bafetinib is a small molecule tyrosine kinase
inhibitor in development for chronic myeloid leukemia (CML)
[20]. It has been designed to potently and specifically inhibit BCR-
ABL and the SRC family kinase (SFK) LYN, but no other SFKs,
with the purpose of displaying an improved safety profile over
multi-kinase and pan-SFK inhibitors, such as dasatinib, while
retaining the advantageous dual mechanism of action. We have
recently characterized the detailed target profile of bafetinib by
chemical proteomics and to interpret the complex dataset
obtained is challenging. One of the most popular methods for
distinguishing (and potentially quantifying) specific drug targets
from non-specific background proteins is the competition of
soluble drug molecules with the affinity matrix for drug binding
proteins (Figure 1) [21–23]. Comparison of the protein eluates
from a competed and a non-competed drug pulldowns will
highlight specific binders, while non-specific binding proteins will
not be affected. However, even after correct identification and
potentially determination of quantitative interaction parameters
for distinct drug-protein pairs, a global or mechanistic under-
standing of drug effects is but a distant goal requiring some
sophisticated experimental and/or theoretical follow-up. Our
theoretical effort advances significantly our mechanistic under-
standing of the effects of bafetinib and provides others with a
computational strategy applicable to different drug profiles.
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Our computational approach to predict the impact of bafetinib
on a functional network is based on the human protein-protein
interaction network, on the annotation of its nodes and on a drug
target profile associated with an affinity measure.
Human protein interaction network
The network is constructed from protein-protein interactions
found in the public interaction databases HPRD, MINT, Intact,
DIP and BioGRID [24–28]. Furthermore, it is supplemented with
published interactions of the BCR-ABL core complex which is the
primary target of bafetinib in chronic myeloid leukemia (CML)
[29]. The resulting undirected network contains 11505 proteins
and 80363 interactions.
Uniform functional sub-network
The human network of all known protein-protein interactions is
associated with its biological processes of gene ontology (GO)
derived from UniProtKB and Entrez Gene [30–32]. All ancestors
of the GO tree are assigned in addition to achieve a complete and
consistent annotation. In total, the human interaction network
consists of 6390 different BP terms. 8939 (78%) nodes of the
human interactome are at least associated with one biological
process. A uniform functional sub-network is a connected fraction
of the interactome, in which all the proteins share the same
function, i.e., one unique GO term. The interactome can contain
multiple disjoint functional sub-networks for the same annotation.
Drug target profile
The recently published drug target profile of the kinase inhibitor
bafetinib measured in the cell line K562 is used [33]. Rix et al took
three quality criteria into account: (1) The drug target profile is
devoid of proteins in the K562 core proteome. (2) No frequent
hitters are included. (3) The proteins must be seen in replicates. In
addition, splice variants and protein fragments are excluded. The
33 proteins are listed in Table S1.
Perturbation of function
Bafetinib can impact the uniform functional sub-networks in
two ways via its targets (Figure 2):
(1) The drug inhibits directly a node of the uniform functional
sub-network.
(2) The drug target interacts with the uniform functional sub-
network at its periphery. To consider also complexes and
cascades, drug targets which are linked via other drug targets
to the functional sub-network are included.
It is difficult to predict which mode of perturbation has a higher
impact. Directly inhibiting a pivotal sub-network member can
completely disrupt a function. Nonetheless, biological signaling
networks often have multiple alternative routes and protein
isoforms to rescue the cell. Drug targets acting at the periphery
can modify significantly the function through interaction or
modulation of a modification, e.g., phosphorylation. By this
Figure 1. Chemical proteomics without (A) and with (B) soluble
drug competition. (A) The drug (blue) bound to a matrix (grey)
retains the drug targets (green) and secondary binders (orange). Most
unspecific proteins (red) are washed of but some could stick to the
matrix. The retained proteins are analyzed with MS/MS. (B) If the soluble
drug is supplemented, it blocks the binding pocket of its target yielding
a reduced amount of pulled-down proteins that are specific drug
binders. Only sticky unspecific proteins and weak drug targets are
retained.
doi:10.1371/journal.pcbi.1001001.g001
Figure 2. The perturbed functional network is a protein-
protein interaction (blue edges) network. This network includes
the uniform functional sub-network (triangular nodes) which shares one
biological function and all drug targets (grey nodes) interacting with it.
Bafetinib (Bafe) can impact nodes (red border) in the uniform functional
sub-networks in two ways: Either the drug inhibits directly a node in the
uniform functional sub-network (1) or it modulates the function
through peripherally interacting drug targets (2).
doi:10.1371/journal.pcbi.1001001.g002
Author Summary
Protein interaction data are accumulating rapidly and,
although imperfect and incomplete, they provide a
valuable global description of the complex interplay of
proteins in a human cell. In parallel, modern proteomics
technologies make it possible to measure in an unbiased
manner the protein targets of a drug. Such data reveal
multiple targets in a view that contrasts with a previously
prevalent paradigm that drugs had single – or a very
limited number of – targets. In this context of newly
available systems level data and more precise and
complete information about drug interactions, it is natural
to try to determine the global perturbation exerted by a
drug on a human cell to identify potential side effects and
additional indications. We present a computational meth-
od that aims at making such predictions and apply it to
bafetinib, a recently developed leukemia drug. We show
that meaningful predictions of additional applications to
other cancers or resistant cases and likely side effects are
obtained that are not straightforward to determine with
existing algorithms. Our method has a strong potential to
be applicable to other drugs.
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possible. Furthermore, functional boundaries are often loosely
defined and incompletely annotated. We thus treat both
perturbation modes equally and therefore the perturbed functional
sub-network (Figure 2) combines the uniform functional sub-
networks with all interactions to the peripheral drug targets. This
combination could result in joining otherwise disjoint uniform
functional sub-networks via a drug target as linker (see MAPK14
in Figure 3). The direct targets are already members of the
uniform functional sub-networks.
Scoring the impact of bafetinib
We define a score snet which predicts how strong functional sub-
networks are perturbed by bafetinib. For this purpose different
features of the perturbed functional sub-network are combined.
The first feature describes how frequent the annotation is
present in the sub-network. Peripheral drug targets don’t share the
functional annotation (Figure 2), hence they dilute the functional
annotation of the sub-networks. To ensure that the function is not
underrepresented in the network, a first factor of the score is the
ratio of the number nannot,net of nodes which have a specific
annotation to the total size nnet of the perturbed functional
sub-network.
The second feature puts the drug impact in relation to the sub-
network size. Generic biological functions result in very big sub-
networks, in which the drug targets play overall no important role
anymore. Furthermore, the drug should preferentially perturb a
function at several different points. Hence, the proportion of the
number ndrug,net of drug target nodes to the number nnet of all
nodes in the perturbed functional sub-network resembles a good
measure.
Lastly, the binding affinity at of bafetinib to its targets or the
potency of inhibition is important for effective perturbation. In
theory, the affinities can be measured in biochemical assays which
are not always available. However, we propose hereafter an ad hoc
affinity measure derived from chemical proteomics data directly.
Figure 3. Perturbed functional sub-network based on induction of apoptosis by intracellular signals. In the protein-protein interaction
(edges) network, the Bafetinib profile (grey nodes) perturbs the biological process (triangular nodes) which is pivotal in BCR-ABL dependent CML. The
drug affinity (at) is indicated by the node size. Kinases in the target profile have a red label. Proteins of the uniform functional sub-network interacting
with inhibited kinases are shown with a red node border. K562 cells contain ABL1 and its fusion protein BCR-ABL which is not found by the algorithm
in this sub-network. However, ABL1 pulldown is hidden by BCR-ABL and hence missed as target. Western plots proved ABL1 as a competed target
[33] and hence influences are indicated with thin red borders.
doi:10.1371/journal.pcbi.1001001.g003
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targets in the perturbed functional sub-network Tdrug,net divided by
the overall affinity of all possible drug targets Tdurg. Combining
these factors results in a score for each disrupted functional
network:
snet~
nannot,net
nnet
|
ndrug,net
nnet
|
P
t[Tdrug,net
at
,
P
t[Tdrug
at ð1Þ
The last two factors of equation (1) have an additional role and
benefit. Mass spectrometry detection as used in chemical
proteomics does not detect direct drug interactors only; it can
also detect secondary interactors, i.e. proteins that bind to direct
drug interactors. Without prior knowledge, it is difficult to
distinguish between direct and indirect interactors but we believe
that it is advantageous to use the complete target profile of
bafetinib as it embeds the true drug targets into a specific context
and increases the crosstalk with annotated nodes of the sub-
networks (the second factor in equation (1) increases). The affinity
factor ensures that also true and strong drug targets are part of the
sub-network.
Affinity score at for chemical proteomics
The affinity of bafetinib to its targets is used to score the impact
on sub-networks in equation (1). The higher the protein amount in
mass spectrometry analysis, the higher the number of different
detected peptides covering the protein sequence [34]. Hence, the
peptide count pt of each protein is a rough estimate of the amount
of pulled-down protein. If soluble bafetinib is supplemented, the
soluble drug blocks the binding pocket of its target yielding a
reduced amount of pulled-down proteins that are specific drug
binders (Figure 1) and thus, their peptide counts pt,comp decrease.
This observation is expressed in the first factor of the affinity score.
Since in chemical proteomics the drug is always present at a large
excess of constant concentration, it is only possible to distinguish
the affinities of completely competed proteins by taking the protein
amount into account. To down weigh this parameter influence,
the logarithm is applied to pt. Thus, the affinity score can be
expressed by the following equation:
at~ 1{
pt,comp
pt
  
|ln pt ðÞ ð 2Þ
Due to the reduced complexity of the competed pull-down, it can
sporadically happen that pt,comp.pt. This case is seen as no
competition and thus the affinity is set to 0.
Randomization
An empirical p-value is calculated via randomization of the
interactome. First, the interaction partners of each node are
randomly selected. It is ensured that the degree of each node remains
constant. Second, the annotation is randomly assigned to the nodes,
while the total number of each term is preserved. The presented
algorithm is applied to 500 random instances of the interactome. The
empirical p-value is calculated from the fraction of randomized
interactomes containing a sub-network with a score equal or better to
the tested score divided by the total number of random instances.The
highest score of all the random instances smax, rand is 0.124.
R-Package
The presented approach is programmed in the statis-
tical environment R/Bioconductor and available at http://
bioinformatics.cemm.oeaw.ac.at/drugDisruptNet [35,36]. The
provided R package depends on graph, RBGL, snow and GO.db
[37–39]. Parallelization is done with snow to generate and score
random instances [40]. Additionally, the above described data and
the results are stored as R data objects.
Visualization and comparison
Networks are visualized with Cytoscape [41]. For comparison,
classical GO/KEGG/Biocarta enrichment analysis of sets are
performed with DAVID [18].
Results and Discussion
We present a novel strategy to analyze the mechanisms of action
of bafetinib. The target profile is weighted with respect to its drug
affinity and its impact on protein interaction networks is scored.
Ten perturbed functional sub-networks are scored higher than any
sub-network of the 500 randomized interactomes (smax, rand=
0.124), see Table 1 and Figure 3, 4 and supplementary Figure S1,
S2. The sub-networks do not necessarily contain all the
components of a specific function since several disjoint functional
sub-networks can be constructed. Bafetinib is designed to treat
BCR-ABL dependent chronic myeloid leukemia (CML). Consti-
tutively active BCR-ABL interferes strongly with apoptosis in
malignant cells. We catch this process in our significantly
perturbed sub-networks at rank 6 (Table 1). Furthermore, MAP
kinase signaling can also be brought together with pathogenesis
and treatment of CML. The top ranked perturbation of
‘‘Epidermal growth factor receptor (EGFR) signaling pathways’’
and ‘‘Insulin receptor signaling pathway’’ suggest potential novel
domains of treatment for bafetinib and ‘‘heart development’’
indicates a putative side effect. The hit signaling pathways further
play important roles in the general perturbed processes of aging,
extracelluar structure organization and cell cycle. Finally,
phosphorylation is an obvious process to be perturbed by a kinase
inhibitor. We discuss pathogenesis, potential new domains of drug
treatment and putative side effects of bafetinib in more details.
Inactivated apoptosis signaling plays a pivotal role in BCR-ABL
dependent CML pathogenesis [42] and is well represented in the
significant sub-networks. The perturbed functional sub-network of
apoptosis (Figure 3) is disrupted by inhibition of ABL2, MLTK,
LYN and MAPK14 (p38a). These kinases are not annotated
themselves as ‘‘induction of apoptosis by intracellular signals’’ but
act at the periphery of the uniform functional sub-network. K562
cells express ABL1, a central node of the network, and its fusion
protein BCR-ABL. High amounts of BCR-ABL hide specific
ABL1 detection with mass spectrometry. However, western blots
proved ABL1 as a competed target of bafetinib in K562 [33].
Hence, the score of perturbation underestimates the impact of
bafetinib on apoptosis in CML.
The impact of bafetinib on apoptosis in CML is manifested with
5 targeted kinases at the periphery (Figure 3). The method strongly
prefers networks which are attacked by several high affinity drug
targets. In theory, a single perturbation might be enough to
significantly interfere with a biological function. However,
biological signaling networks are often highly redundant thus
requiring perturbation at several points in order to observe an
effect [43]. Hence, promiscuous drugs like dasatinib are very
successful in CML and other cancers and the multi-targeted
networks are likely to be of high relevance in drug treatment.
Even if we know that the drug has an inhibitory effect on the
target kinases, we cannot predict without additional knowledge
whether missing phosphorylation has an enhancing or decreasing
effect on the biological process. The constitutively active kinase
Perturbation by Bafetinib
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counteracts this behavior [44]. Inhibition of LYN has a similar
effect in this context [45]. Contrary to this, MAPK14 inhibition
rescues cells from apoptosis [46]. Only through the complex
interplay of different signals, the malignant cells die upon
treatment as desired. Hence, visualization of the network together
with its disturbers strongly aids in interpreting their influence. This
is a great advantage compared to simple GO enrichment analysis
which does not display the relationship of the proteins to each
other.
The top ranked perturbed functional sub-network is based on
the epidermal growth factor receptor (EGFR) signaling pathway
(Figure 4). It is peripherally interacting with six kinases of the drug
profile. Three additional kinases are directly interacting with
EGFR but also interfering with 7 further proteins of the signaling
cascade. Additionally, the crosstalk between the pulled down non-
kinase members and the functional network is very high. In total
13 out of 33 EGFR signaling components (39%) are interacting
with the drug profile.
EGFR is not expressed in hematopoietic cells (such as K562) but
this sub-network strongly suggests that bafetinib has the potential
to interfere with EGFR signaling for instance in lung cancer cells.
Recently, it was shown through the combination of chemical
proteomics, phosphoproteomics and functional genomics that
dasatinib, a broad-spectrum kinase inhibitor, leads to apoptosis in
lung cancer cells via inhibition of SRC, EGFR, FYN and, notably,
LYN [47]. Therefore, it is possible that also bafetinib might have a
pro-apoptotic effect on these cells as it is also a potent inhibitor of
LYN. While expression of dasatinib-insensitive gatekeeper mutants
of DDR1 (or ABL1) did not rescue the H292 lung cancer cell line
from dasatinib action, the role of DDR1 might be quite different in
primary lung cancer cells as several recent reports described this
receptor tyrosine kinase to be one of the most highly expressed and
phosphorylated kinases in primary lung tumor specimens [48,49].
Thus, it is conceivable that bafetinib might exert pro-apoptotic
effects on lung cancer cells, and it might do so through
simultaneous inhibition of LYN and DDR1.
Second highest is the perturbation of insulin receptor signaling
pathway. It was suggested that bafetinib, CGP76030 and nilotinib
might overcome imatinib resistance in blast crisis patients which
feature BCR-ABL gene amplification [50]. Phase 1 studies could
not verify this yet [51]. However, we propose to treat only the
subgroup of CML blast crisis patients which expresses IGF1R with
bafetinib. The drug targets are strongly interacting with the insulin
receptor signaling pathway which maintains survival of hemato-
poietic cells through IGF1R (supplementary Figure S1). The
IGF1R expression frequency is strongly increased in blast crisis
patients (73%). Inhibition of IGF1R was shown in imatinib-
resistant CML to induce apoptosis [52]. IGF1R is not a known
direct target of bafetinib but attacking several downstream
components simultaneously might show a similar effect as a direct
IGF1R inhibition.
A potential side effect of several tyrosine kinase inhibitors, like
sunitinib and dasatinib, is an increased risk for cardiotoxicity [53].
Observed toxicity in rats can be a result of higher concentration
than used in patients [54]. Nevertheless, perturbation of the ‘‘heart
development’’ network (Figure S2) indicates some possible risks
which should be closely monitored during clinical trials.
We validated the robustness of the algorithm by following the
rank of the biological process upon leaving-one-out (supplemen-
tary Figure S3). The ranks of the first five sub-networks (Table 1)
are generally stable upon loss of a node. High affinity targets are
essential to the phenotype which results in increased sensitivity of
highly ranked terms to high affinity targets. On the contrary,
weaker binders, which are not competed away with free drug,
have only a modest effect on the rank.
Furthermore, we investigated the effect of hubs on the sub-
network ranks, which might exert an influence on the phenotype
upon inhibition. It is not clear whether hubs are, in the context of
our analysis, highly important or ‘‘general signal diluters’’.
Therefore, we weighted up and then down the affinity of the
targets by log10 of their node degree. Multiply by this factor, i.e.
increasing hubs importance, the top 6 sub-networks remain
unchanged and ‘‘cell cycle arrest’’ even improved its rank by one.
The others sub-networks were substituted by ‘‘response to insulin
stimulus’’, ‘‘response to peptide hormone stimulus’’ and ‘‘cellular
response to hormone stimulus’’, which are in line with insulin
receptor signaling. Upon down-weighting by division, the top 4
sub-networks still remained unchanged. We conclude for robust-
ness and reasonable independence of local topology. In other
words, the function of the sub-network at hand seems to play a
strong role in scoring, which is appropriate.
To show the general interest of our method we applied the
algorithm to data we published recently analyzing lung cancer
(HCC297) treatment with dasatinib [47], another kinase inhibitor.
Interestingly, dasatinib is highly promiscuous and pulls down 176
proteins (33 kinases) compared to the 33 proteins of bafetinib. In
addition, free compound competition data were not available in
Table 1. Significantly perturbed functional sub-networks named by their basic function.
Perturbed functional sub-networks Nodes Targets (competed) Score snet
Epidermal growth factor receptor signaling pathway 57 25 (7) 0.213
Insulin receptor signaling pathway 68 26 (7) 0.198
Aging 96 29 (7) 0.185
Regulation of MAP kinase activity 94 22 (7) 0.162
Induction of apoptosis by intracellular signals 53 19 (5) 0.135
Extracellular structure organization and biogenesis 81 21 (6) 0.135
MAPKKK cascade 188 29 (8) 0.131
Heart development 104 21 (7) 0.127
Protein amino acid autophosphorylation 71 21 (5) 0.126
Cell cycle arrest 73 21 (5) 0.125
(Randomization: N=500; p-value,0.002).
doi:10.1371/journal.pcbi.1001001.t001
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were available instead (Table S2A of Ref. [47]). The log10 of the
IC50s (in the nM range) were used to weight the effect of dasatinib
on the kinases. Analysis results in 681 significantly hit sub-
networks due to the huge kinase profile (P-value,0.002, Table
S2). Even though more than 5% of the human kinases are targeted
by dasatinib and, subsequently, many sub-networks are signifi-
cantly impacted, the top disrupted sub-networks are insightful. For
instance, the top 10 ranked biological processes are centered on
cell cycle arrest, cell growth and apoptosis. In the highest ranked
sub-networks, SRC, LYN and EGFR play a pivotal role, which is
absolutely consistent with our experimental data where these three
proteins were shown with dasatinib gate-keeper mutants to
strongly contribute to cell viability of HCC297 [47]. These results
show that the algorithm can provide informative data even in very
challenging situations.
In comparison to our approach, classical GO enrichment
analysis (p-value,0.01) of the 33 bafetinib drug targets result in 33
significant biological processes with high redundancy in the GO
tree (supplementary Table S3). Basically, they represent 3 GO
terms: cytoskeleton organization (especially actin filament),
phosphorylation and regulation of stress-activated protein kinase
signaling pathway. Except phosphorylation which is obvious in a
target profile of a kinase inhibitor there is no overlap with the
Figure 4. The bafetinib targets (grey nodes) perturb EGFR signaling which suggests a new application in lung cancer. The drug profile
interferes with many nodes of the uniform function sub-network (triangular nodes). The drug affinity is indicated by the node size (a large node
means high affinity). Kinases in the target profile have a red label. Proteins of the uniform functional sub-network interacting with inhibited kinases
are shown with a red node border. EGFR expressing cells are not known to carry the fusion protein BCR-ABL which diminishes the influence of BCR-
ABL on the network (dashed lines).
doi:10.1371/journal.pcbi.1001001.g004
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organization contains competed and non-competed members of
the target profile. The combined attack power of few competed
kinases is too low to see perturbation of the large uniform
functional sub-network (387 members) which is based on
cytoskeleton organization. Enrichment analysis with KEGG and
Biocarta pathways (p-value,0.01) yielded no hit.
In contrast to GO enrichment analysis, the presented method
does not as much rely on accurate annotations. Possible missing
annotations of drug targets interacting at the periphery with a
functional sub-network have only a minor effect on the score.
However, we would like to point out that boundaries of pathways
and biological processes are very diffuse. Crosstalk between
different signaling cascades and metabolic pathways is essential
for a living cell. Integrating protein interactions to peripheral drug
targets provides a way out of this dilemma and can catch therefore
more relevant processes than GO enrichment. Alternatively,
augmenting the drug target profile with their direct interactors,
results in a set of 831 proteins. GO enrichment analysis
(p-value,0.01) of this set results in 676 biological processes (Table
S4). Again the first hits are related to general phosphorylation
which is obvious for a kinase inhibitor profile. At the ninth rank
‘‘regulation of programmed cell death’’ which is related to
perturbed apoptosis is presented with 127 proteins of the
augmented set. The highest scored perturbed sub-network of
EGFR signaling is only found at position 368. Even though the
disrupted processes are detected with the augmented GO analysis,
their ranks are so bad that they would not be considered as
relevant. Our approach thus picks the most relevant perturbed
functional networks and allows for insights beyond traditional GO
enrichment analysis.
Competition experiments in chemical proteomics provide an
additional layer of security to the drug target profile. Secondary
and unspecific binders are difficult to distinguish from true drug
targets. They are often similar in the range of peptide counts and
other properties. The competition with a soluble drug and our
affinity score helps in identifying biological target proteins.
Interestingly, unspecific binders influence the perturbation algo-
rithm only marginally since the proteins are dispersed all-over the
interactome and have no affinity to a specific uniform functional
sub-network. Furthermore, their binding affinity score is 0. On the
contrary, secondary binders of true drug targets increase the
crosstalk to the functional sub-network which is attacked by the
true target. Hence they can be used advantageously embedding
the true targets in a specific context.
In conclusion, we identified successfully known mechanisms in
CML as well as potential new applications and possible side-
effects. We believe that the proposed computational approach can
shed light in mechanisms of other drugs including highly
promiscuous compounds and when soluble compound competi-
tion data are lacking. Hence, we provide an R package at http://
bioinformatics.cemm.oeaw.ac.at/drugDisruptNet.
Supporting Information
Figure S1 The bafetinib targets (grey nodes) disrupt the insulin
receptor signaling pathway. The drug profile interferes with many
nodes of the uniform function sub-network (triangular nodes). The
drug affinity is indicated by the node size (large node equals high
affinity). Kinases in the target profile have a red label. Proteins of
the uniform functional sub-network interacting with inhibited
kinases are shown with a red node border.
Found at: doi:10.1371/journal.pcbi.1001001.s001 (0.47 MB TIF)
Figure S2 The bafetinib targets (grey nodes) disrupt the heart
development suggesting putative risk factors. The drug profile
interferes with many nodes of the uniform function sub-network
(triangular nodes). The drug affinity is indicated by the node size
(large node equals high affinity). Kinases in the target profile have
a red label. Proteins of the uniform functional sub-network
interacting with inhibited kinases are shown with a red node
border.
Found at: doi:10.1371/journal.pcbi.1001001.s002 (0.49 MB TIF)
Figure S3 Leave-one-out analysis. The ranks of the first five
subnetworks (Table 1) are generally stable upon loss of a node.
High affinity targets (left) are essential to the phenotype which
results in increased sensitivity of highly ranked terms to high
affinity targets. On the contrary, weaker binders (right) have only a
modest effect on the rank.
Found at: doi:10.1371/journal.pcbi.1001001.s003 (0.11 MB PDF)
Table S1 Bafetinib (INNO-406) drug target profile.
Found at: doi:10.1371/journal.pcbi.1001001.s004 (0.06 MB
DOC)
Table S2 Significantly hit sub-network by the highly promiscu-
ous drug dasatinib.
Found at: doi:10.1371/journal.pcbi.1001001.s005 (0.12 MB XLS)
Table S3 Classical gene ontology (GO) enrichment analysis
(p-value,0.01). The secondary and unspecific binders have a large
influence on GO enrichment analysis.
Found at: doi:10.1371/journal.pcbi.1001001.s006 (0.04 MB
DOC)
Table S4 Classical gene ontology (GO) enrichment analysis on
all direct interactors of the drug profile (p-value,0.01).
Found at: doi:10.1371/journal.pcbi.1001001.s007 (0.40 MB XLS)
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